Cognoa receives FDA Breakthrough Device designations
Cognoa announced that its first digital diagnostic and digital therapeutic devices to treat autism have received Breakthrough Device designations from the FDA.
Cognoa, located in Palo Alto CA, is developing methods for evaluating a subject for a developmental condition that can be tuned to control the tradeoff between coverage and reliability. Cognoa is also developing a digital personalized medicine system that uses digital data to assess or diagnose symptoms of a subject to provide personalized therapeutic interventions and improved diagnoses.
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…